By Devika Patel
Knoxville, Tenn., Nov. 29 - Sharon Bio-Medicine Ltd. informed the Bombay Stock Exchange that it has priced $16.5 million of five-year 0% convertible bonds with a 38% initial conversion premium.
The notes are convertible at Rs. 315 per share.
Silverdale Services Ltd., London, was the lead manager for the offering, and Fortune financial Service (India) Ltd. Mumbai was the Indian adviser.
Sharon Bio-Medicine is a Mumbai, India-based pharmaceutical company.
| Issuer: | Sharon Bio Medicine Ltd.
|
| Issue: | Convertible bonds
|
| Amount: | $16.5 million
|
| Maturity: | Dec. 4, 2012
|
| Coupon: | 0%
|
| Price: | Par
|
| Conversion premium: | 38%
|
| Conversion price: | Rs. 315
|
| Underwriter: | Silverdale Services Ltd, London
|
| Settlement date: | Nov. 27
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
